HIF1A and sarcopenia: To test whether HIF-1α activation would affect sarcopenia by preventing the onset of symptoms, human skeletal muscle cells from sarcopenic patients were isolated and treated with 50 μM FG-4592, a PHDs inhibitor, for 24 h [29].